MedTrace Logo

New Markers for Treatment Response to Radiotherapy in Prostate Cancer

NCT06159998 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-12-07

No results posted yet for this study

Summary

The actual follow-up of patients undergoing definite radiotherapy for prostate cancer includes regular measurements of prostate specific antigen (PSA). Successful radiotherapy is critically dependent on local control of cancer; however, PSA takes 2-3 years to reach a nadir after therapy. We aim at collecting blood/urine after prostate massage before, and after radiotherapy in order to define new markers predicting local control earlier and more precisely than PSA.

Conditions

Sponsors & Collaborators

  • University of Basel

    lead OTHER

Principal Investigators

  • Cyrill A Rentsch, MD-PhD · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-07-31
Completion
2019-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159998 on ClinicalTrials.gov